SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Mar 10, 2020

PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: March 10, 2020 · CIK: 0001614744 · Accession: 0001213900-20-005825

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-235729

Date

March 10, 2020

Author

H.C. Wainwright & Co., LLC

Form

CORRESP

Company

PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey Gabor RE: Kitov Pharma Ltd. Registration Statement on Form F-1 Filed December 27, 2019, as amended March 10, 2020 Concurrence in Acceleration Request File No. 333-235729

Dear Mr. Gabor:

In connection with the above mentioned Registration Statement on Form F-1 of Kitov Pharma, Ltd., the undersigned, as placement agent of the offering described therein, hereby concurs in the request for acceleration of the effective date and time of the above-mentioned Registration Statement on Form F-1 to 5:15 p.m. Eastern Time on Wednesday, March 11, 2020, or as soon thereafter as practicable, pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Act”). The undersigned affirms that it is aware of its obligations under the Securities Act in connection with this offering.

The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities and Exchange Act of 1934, as amended.

Very truly yours,
H.C. Wainwright & Co., LLC

Show Raw Text

CORRESP
1
filename1.htm

H.C.
Wainwright & Co., LLC

430 Park Avenue

New York, New York 10022

March 10, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street N.E.

Washington, D.C. 20549

Attention: Jeffrey Gabor

    RE:
    Kitov Pharma Ltd.  Registration Statement on Form F-1
Filed December 27, 2019, as amended March 10, 2020

    Concurrence in Acceleration Request

    File No. 333-235729

Dear Mr. Gabor:

In connection with the above mentioned Registration
Statement on Form F-1 of Kitov Pharma, Ltd., the undersigned, as placement agent of the offering described therein, hereby concurs
in the request for acceleration of the effective date and time of the above-mentioned Registration Statement on Form F-1 to 5:15
p.m. Eastern Time on Wednesday, March 11, 2020, or as soon thereafter as practicable, pursuant to Rule 461 of the Securities Act
of 1933, as amended (the “Act”). The undersigned affirms that it is aware of its obligations under the Securities Act
in connection with this offering.

The undersigned advises that it has complied
and will continue to comply with the requirements of Rule 15c2-8 under the Securities and Exchange Act of 1934, as amended.

    Very truly yours,

    H.C. Wainwright & Co., LLC

    By:
    /s/ Mark W. Viklund

    Name:
    Mark W. Viklund

    Title:
    Chief Executive Officer

SecProbe.io